Skip to content
FinTech Series A Founded 2015

Fin

Beijing Yimiao Shenzhou Pharmaceutical Technology is a developer of CAR-T cell therapy and gene cell drugs for the treatment of cancer and malignant tumors. The company applies chimeric antigen receptor T-cell (CAR-T) technology to develop targeted immunotherapies for oncology applications. It also develops a gene engineering vector technology platform for the delivery of therapeutic genes, enabling the creation of…

📍 Paris, France · Digital Remittance

Funding snapshot

Last roundSeries A
Amount$20M
Date9 September 2021
Total raised$20M
Team size94

About

Beijing Yimiao Shenzhou Pharmaceutical Technology is a developer of CAR-T cell therapy and gene cell drugs for the treatment of cancer and malignant tumors. The company applies chimeric antigen receptor T-cell (CAR-T) technology to develop targeted immunotherapies for oncology applications. It also develops a gene engineering vector technology platform for the delivery of therapeutic genes, enabling the creation of advanced cell therapy products. The company focuses on leveraging genomics, immunotherapy, and cell therapy approaches to address unmet needs in cancer treatment. Founded in 2015 and headquartered in Haidian, Beijing, China, the company has raised $42.8 million in Series D funding from investors including China Life Insurance, GF Securities, SDIC Venture Capital Management, Shougang Fund, AAMA Chamber of Commerce, and Sherpa Ventures.

Business model

Digital Remittance > Internet First Platforms > Diversified > Cryptocurrency

Founders & team highlights

$5M+ Club Founder,

Founder with Prior Acquisition,

Serial Founder

Team background

Company Wise > Facebook, Bain,

Top Rated Teams > Serial Entrepreneur,

College Wise > Harvard University

Institutional investors

Coatue First Round Capital Accel Kleiner Perkins

Latest coverage

No articles yet.

Raising like Fin?

Analyze your pitch deck before your next raise.

Analyze My Deck →